Randomized, open-label, multiple-dose study to evaluate the pharmacokinetics of atazanavir administered twice-daily in health subjects.

Trial Profile

Randomized, open-label, multiple-dose study to evaluate the pharmacokinetics of atazanavir administered twice-daily in health subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2011

At a glance

  • Drugs Atazanavir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Nov 2007 Status changed from in progress to completed.
    • 03 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top